Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study
2018 · Annals of Oncology · 756 citations
https://doi.org/10.1093/annonc/mdy517
P
P. Schmid
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
9
Papers
1.3K
Citations
5
h-index
5
i10-index
P. Schmid is an academic researcher from Queen Mary University of London. The author has contributed to research in topics: Advanced Breast Cancer Therapies & HER2/EGFR in Cancer Research & Cancer Immunotherapy and Biomarkers. The author has an h-index of 5, co-authored 8 publications.
Papers by this author
worksFirst-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis
2021 · Annals of Oncology · 443 citations
https://doi.org/10.1016/j.annonc.2021.05.355
623TiP A single-arm phase 2 study of evorpacept in combination with trastuzumab and chemotherapy in participants with HER2-positive metastatic breast cancer (mBC) (ASPEN-09-03)
2025 · Annals of Oncology · 0 citations
https://doi.org/10.1016/j.annonc.2025.08.1045
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat